TY  - JOUR
A1  - Rödel, Franz
A1  - Zhou, Shengtao
A1  - Győrffy, Balász
A1  - Raab, Monika
A1  - Sanhaji, Mourad
A1  - Mandal, Ranadip
A1  - Martin, Daniel
A1  - Becker, Sven
A1  - Strebhardt, Klaus
T1  - The prognostic relevance of the proliferation markers Ki-67 and Plk1 in early-stage ovarian cancer patients with serous, low-grade carcinoma based on mRNA and protein expression
T2  - Frontiers in oncology
N2  - Since type and duration of an appropriate adjuvant chemotherapy in early-stage ovarian cancer (OC) are still being debated, novel markers for a better stratification of these patients are of utmost importance for the design of an improved chemotherapeutical strategy. In contrast to numerous cancer studies on cellular proliferation based on the immunohistochemistry-driven evaluation of protein expression, we compared mRNA and protein expression of two independent markers of cellular proliferation, Ki-67 and Plk1, in a large cohort of 243 early-stage OC and their relationship with clinicopathological features and survival. Based on marker expression we demonstrate that early-stage OC patients (stages I/II, low-grade, serous) with high expression (Ki-67, Plk1) had a significantly shorter progression-free survival (PFS) and overall survival (OS) compared to patients with low expression (Ki-67, Plk1). Remarkably, based on mRNA expression this significant difference got lost in advanced stages (III/IV): At least for PFS, high levels of Ki-67 and Plk1 correlate with moderately better survival compared to patients with low expressing tumors. Our data suggest that in addition to Ki-67, Plk1 is a novel marker for the stratification of early-stage OC patients to maximize therapeutic efforts. Both, Ki-67 and Plk1, seem to be better suited in early-stages (I/II) as therapeutical targets compared to advanced-stages (III/IV) OC.
KW  - polo-like kinase 1
KW  - Ki-67/MIB1
KW  - ovarian cancer
KW  - prognosis
KW  - mRNA and protein expression
Y1  - 2020
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/57193
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-571936
SN  - 2234-943X
VL  - 10
IS  - 558932
PB  - Frontiers Media
CY  - Lausanne
ER  -